Key result
Elevated aortic stiffness linked to ~114% greater MACE risk in diabetic patients with suspected ischemia.
Why the study?
Prognostic data regarding aortic stiffness in patients with diabetes mellitus undergoing stress perfusion CMR were lacking.
Does elevated aortic stiffness measured by CMR predict MACE in patients with diabetes mellitus and suspected myocardial ischemia?
Cohort (n=424)
No
Does elevated aortic stiffness measured by CMR predict MACE in patients with diabetes mellitus and suspected myocardial ischemia?
Hazard Ratio: 2.14 (95% CI 1.48–3.09)
Absolute Event Rate: 38.2% vs 19.7%
p-value: p=< 0.001
Aortic stiffness measured by CMR provides independent and incremental prognostic value for predicting MACE in diabetic patients with suspected myocardial ischemia.
Supports independent prognostic value of CMR PWV in diabetes; hypothesis-generating and should not yet change practice.
BACKGROUND AND AIMS: Cardiovascular magnetic resonance (CMR) comprehensively assesses aortic stiffness and myocardial ischemia in a single examination. Aortic stiffness represents a subclinical marker of cardiovascular risk in the general population, including patients with diabetes mellitus. However, there is no prognostic data regarding aortic stiffness in patients with diabetes mellitus undergoing stress perfusion CMR. METHODS: Consecutive patients with diabetes mellitus with suspected myocardial ischemia referred for adenosine stress perfusion CMR with aortic pulse wave velocity (PWV) during 2010-2013 were studied. The primary outcome was major adverse cardiovascular events (MACE), defined as the composite of cardiac mortality, nonfatal myocardial infarction (MI), hospitalization for heart failure, coronary revascularization (> 90 days post-CMR), and ischemic stroke. The secondary outcome was hard cardiac events, defined as the composite of cardiac mortality and nonfatal MI. RESULTS: A total of 424 patients (median follow-up 7.2 years) were included. The mean PWV was 12.16 ± 6.28 m/s. MACE and hard cardiac events occurred in 26.8% and 9.4% of patients, respectively. Patients with elevated PWV (> 12.16 m/s) had a significantly higher incidence of MACE (HR 2.14 [95%CI 1.48, 3.09], p < 0.001) and hard cardiac events (HR 2.69 [95%CI 1.42, 5.10], p = 0.002) compared to those with non-elevated PWV. Multivariable analysis demonstrated that PWV independently predicts MACE (p = 0.003) and hard cardiac events (p = 0.01). Addition of PWV provided incremental prognostic value beyond clinical data, left ventricular mass index, myocardial ischemia, and late gadolinium enhancement in predicting MACE (incremental χ² 7.54, p = 0.006) and hard cardiac events (incremental χ² 5.99, p = 0.01). CONCLUSIONS: Aortic stiffness measured by CMR independently predicts MACE and hard cardiac events and confers significant incremental prognostic value in patients with diabetes mellitus with suspected myocardial ischemia. Aortic stiffness measurement could potentially be considered as part of a stress perfusion CMR protocol to enhance risk prediction in patients with diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Pengyos et al. (2023) conducted a cohort in Diabetes mellitus with suspected myocardial ischemia (n=424). Elevated aortic pulse wave velocity (PWV > 12.16 m/s) vs. Non-elevated PWV (≤ 12.16 m/s) was evaluated on Major adverse cardiovascular events (MACE), composite of cardiac mortality, nonfatal MI, hospitalization for heart failure, coronary revascularization, and ischemic stroke (HR 2.14, 95% CI 1.48, 3.09, p=< 0.001). Elevated aortic stiffness (pulse wave velocity > 12.16 m/s) significantly increased the risk of major adverse cardiovascular events (HR 2.14) in diabetic patients with suspected myocardial ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: